

**Supplemental Table 1: Baseline characteristics of tesamorelin-treated subjects with ALT or AST > 30 U/L by VAT responder status at week 26**

Variable	VAT responders (n = 177)	VAT nonresponders (n = 80)	P-value
<b>Demographic</b>			
Age (y)	47.6 ± 7.0	47.6 ± 7.1	0.94
Male %	94	93	0.58
Race %			0.43
White	85	79	
Black	7	11	
Asian	0	1	
Hispanic	6	8	
Other	2	1	
Hepatitis C %	6	19	<b>0.002</b>
Any viral hepatitis %	21	38	<b>0.009</b>
Testosterone %	27	29	0.76
Lipid-lowering therapy %	53	48	0.42
<b>Immunologic</b>			
CD4 (cells/mm <sup>3</sup> )	632 ± 318	624 ± 294	0.85
Undetectable viral load %	76	73	0.34
ART %			0.35
NRTI alone	5	6	
NRTI + NNRTI	39	48	
NRTI + PI	41	29	
NRTI + NNRTI + PI	11	10	
Other	5	8	
<b>Metabolic</b>			
BMI (kg/m <sup>2</sup> )	28.7 ± 3.6	29.6 ± 4.6	0.09
VAT (cm <sup>2</sup> )	190 ± 83	202 ± 77	0.27
SAT (cm <sup>2</sup> )	202 ± 108	221 ± 122	0.23
Fat in limbs (kg)	6.1 ± 3.5	7.2 ± 4.4	<b>0.03</b>
Lean body mass (kg)	64.4 ± 8.7	65.5 ± 10.9	0.37
ALT (U/L)	50 ± 20	53 ± 23	0.31
AST (U/L)	37 ± 13	39 ± 15	0.46
IGF-1 (ng/mL)	151 ± 59	158 ± 68	0.46

Mean ± SD

VAT, visceral adipose tissue; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; BMI, body mass index; SAT, subcutaneous adipose tissue; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IGF-1, insulin-like growth factor 1.